Leerink Partnrs Issues Positive Estimate for HIMS Earnings

Hims & Hers Health, Inc. (NYSE:HIMS) – Leerink Partnrs raised their Q4 2024 earnings per share estimates for Hims & Hers Health in a research note issued on Tuesday, October 29th. Leerink Partnrs analyst M. Cherny now expects that the company will post earnings per share of $0.07 for the quarter, up from their prior estimate of $0.06. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.22 per share. Leerink Partnrs also issued estimates for Hims & Hers Health’s Q1 2025 earnings at $0.07 EPS, Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.13 EPS and FY2025 earnings at $0.39 EPS.

Several other brokerages have also recently commented on HIMS. TD Cowen boosted their target price on Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Deutsche Bank Aktiengesellschaft increased their target price on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a report on Wednesday, August 7th. Needham & Company LLC began coverage on Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 target price on the stock. Piper Sandler reiterated a “neutral” rating and set a $18.00 price objective on shares of Hims & Hers Health in a report on Tuesday, August 6th. Finally, Truist Financial boosted their target price on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, July 18th. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.21.

Hims & Hers Health Stock Down 14.3 %

HIMS stock opened at $19.06 on Wednesday. The stock has a market cap of $4.09 billion, a PE ratio of 238.25 and a beta of 1.06. The firm’s 50-day simple moving average is $17.89 and its 200 day simple moving average is $18.00. Hims & Hers Health has a fifty-two week low of $5.76 and a fifty-two week high of $25.74.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, August 5th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. The company had revenue of $315.65 million during the quarter, compared to analyst estimates of $302.43 million. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The business’s revenue was up 51.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.03) earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in HIMS. CWM LLC increased its holdings in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after acquiring an additional 1,054 shares during the period. Arizona State Retirement System raised its holdings in Hims & Hers Health by 3.0% in the second quarter. Arizona State Retirement System now owns 40,344 shares of the company’s stock worth $815,000 after purchasing an additional 1,173 shares in the last quarter. Victory Capital Management Inc. lifted its position in shares of Hims & Hers Health by 6.6% during the second quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock valued at $393,000 after buying an additional 1,212 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Hims & Hers Health by 679.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after buying an additional 1,603 shares in the last quarter. Finally, Swiss National Bank grew its position in shares of Hims & Hers Health by 0.7% in the 1st quarter. Swiss National Bank now owns 281,500 shares of the company’s stock worth $4,355,000 after buying an additional 2,000 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Buying and Selling at Hims & Hers Health

In related news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $16.47, for a total value of $3,110,985.36. Following the completion of the transaction, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at $551,777.94. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $16.47, for a total value of $3,110,985.36. Following the transaction, the chief executive officer now owns 33,502 shares of the company’s stock, valued at approximately $551,777.94. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Oluyemi Okupe sold 11,609 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $14.60, for a total transaction of $169,491.40. Following the sale, the chief financial officer now owns 181,469 shares in the company, valued at approximately $2,649,447.40. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 858,665 shares of company stock valued at $15,148,890 in the last three months. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.